J&J Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine

▴ J&J Announces Collaboration to Expand Manufacturing Capabilities For its COVID19 Vaccine
COVID-19 belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no approved vaccine, treatment or cure for COVID-19.

Johnson & Johnson  today announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigational COVID-19 vaccine candidate. This is the first in a series of prospective global collaboration agreements designed to accelerate manufacturing of Johnson & Johnson's COVID-19 vaccine candidate, and further the Company's goal to supply more than one billion doses of the vaccine globally.

Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said, "We have set a high bar. Johnson & Johnson has committed to rapidly produce and supply more than one billion doses of a safe and effective vaccine globally. Our collaboration with Emergent is proof that we are moving quickly to deliver on that promise."

Under the terms of this manufacturing agreement, Johnson & Johnson is investing to expand drug substance capacity related to the vaccine candidate. Emergent will provide drug substance manufacturing services with its molecule-to-market CDMO offering, beginning in 2020, and will also reserve operations capacity to potentially support commercial manufacturing of Johnson & Johnson's COVID-19 vaccine candidate leveraging Janssen's proven AdVac® and PER.C6® technologies beginning in 2021.

The Company has already begun preparations for clinical vaccine production at its facility in Leiden, the Netherlands, with the aim of initiating Phase 1 human clinical studies of its vaccine candidate in September 2020. Johnson & Johnson will begin production at risk and is committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use.

Simultaneously, Johnson & Johnson is also aiming to rapidly scale up vaccine manufacturing capabilities globally, including increasing capacity in countries outside the U.S. The additional global capacity will assist in the rapid production of a vaccine and enable the supply of more than one billion doses of a safe and effective vaccine to people around the world.

For more than 20 years, Johnson & Johnson has invested billions of dollars in antivirals and vaccine capabilities. The COVID-19 vaccine program leverages Janssen's proven AdVac® and PER.C6® technologies that provide the ability to rapidly develop new vaccine candidates and upscale production of the optimal vaccine candidate. The same technology was used to develop and manufacture the Company's investigational Ebola vaccine and construct our RSV and HIV vaccine candidates which are in Phase 2 or Phase 3 clinical development stages.

COVID-19 belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no approved vaccine, treatment or cure for COVID-19.

Tags : #jj #Collaboration #Manufacturingcapabilities #Vaccine #Covid19

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026